1. Data extraction form.

Review author
Trial registration ID
Dates when study was conducted	If not available, comment "dates not available"
Funding source(s)
Declarations of interest by researchers
Methods	Study design (RCT) Interventions; mean dose prescribed and mean dose received
Participants	Total number, number in each group (sample size) Comparability Setting
Risk of bias	Assessed using risk of bias tool (see Handbook)
Outcomes (as defined in study) Please specify which	Primary outcome Change in distance BCVA in the amblyopic eye following 16(±2) weeks of intervention, as measured in logMAR units on an age‐appropriate acuity test. Secondary outcomes Main secondary outcome: change in BCVA in the amblyopic eye from baseline to 8 (± 2) weeks, as measured in logMAR units on an age‐appropriate acuity test Change in stereoacuity after 16 (± 2) and 8 (± 2) weeks of intervention, measured in octaves (Adams 2009) Adherence to intervention determined by a ratio of usage/prescribed treatment dosage Change in contrast sensitivity interocular difference from baseline to 16 (± 2) weeks, measured using any validated test Proportion of participants experiencing an adverse event of permanent diplopia (double vision) at any time point during intervention
Interventions compared	Intervention 1 = standard care (occlusion or pharmacological blurring) Intervention 2 = binocular treatment
PRIMARY OUTCOME Change in distance BCVA in the amblyopic eye following 16 (± 2) weeks of intervention, as measured in logMAR units on an age‐appropriate acuity test	Intervention 1			Intervention 2
Time point	Total number of participants	Mean	Standard deviation*	Total number of participants	Mean	Standard deviation*
Baseline (note method used to measure BCVA)
BCVA at 16 (± 2)
Or: improvement of BCVA from baseline
SECONDARY OUTCOME Main secondary outcome: change in BCVA in the amblyopic eye from baseline to 8 (± 2) weeks, as measured in logMAR units on an age‐appropriate acuity test	Intervention 1			Intervention 2
Time point	Total number of participants	Mean	Standard deviation*	Total number of participants	Mean	Standard deviation*
Baseline (note method used to measure BCVA)
BCVA at 8 (± 2)
Or: improvement of BCVA from baseline
SECONDARY OUTCOME Change in stereoacuity after 16 (± 2) weeks of intervention, measured in octaves	Intervention 1			Intervention 2
Time point	Total number of participants	Mean	Standard deviation*	Total number of participants	Mean	Standard deviation*
Baseline stereopsis
Change in stereopsis after 16 (± 2)
Change in stereoacuity after 8 (± 2) weeks of intervention, measured in octaves
Time point
Baseline stereopsis
Change in stereopsis after 8 (± 2)
SECONDARY OUTCOME Adherence to intervention determined by a ratio of usage/prescribed treatment dosage	Intervention 1			Intervention 2
Time point	Total number of participants	Mean	Standard deviation*	Total number of participants	Mean	Standard deviation*
End of intervention (specify time from start of treatment)
SECONDARY OUTCOME Change in contrast sensitivity interocular difference from baseline to 16 (± 2) weeks measured using any validated test	Intervention 1	Intervention 2
Time point	Total number of participants	Mean	Standard deviation*	Total number of participants	Mean	Standard deviation*
End of intervention (specify test)
SECONDARY OUTCOME Adverse events (Proportion of participants experiencing an adverse event of permanent diplopia (double vision) at any time point during intervention.)	Intervention 1			Intervention 2
Time point	Total number of participants	Number of affected participants		Total number of participants	Number of affected participants
Permanent diplopia
Time point
Other (specify)
SECONDARY OUTCOME Change in distance BCVA in the amblyopic eye 12 months after cessation of treatment	Intervention 1			Intervention 2
Time point	Total number of participants	Mean	Standard deviation*	Total number of participants	Mean	Standard deviation*
Baseline (note method used to measure BCVA)
12 months after cessation of treatment
Or: improvement of BCVA from baseline to 12 months post‐treatment

ATI: Amblyopia Treatment Index
BCVA: best‐corrected visual acuity
CAT‐QoL: Child Amblyopia Treatment Questionnaire
QoL: quality of life
RCT: randomised controlled trial